ArticleBone marrow transplantation2024
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity.
Article in Bone marrow transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Temporal dynamics of immune effector cell-associated haematotoxicity: Linking early and late cytopenias after chimeric antigen receptor T cells.British journal of haematology · 2026Article
- Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis.BMC medicine · 2026Article
- Redesigning CAR therapy to tackle immune effector cell-associated hematotoxicity.Annals of hematology · 2026Review
- Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact.Bone marrow transplantation · 2026Article
- Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.JCO clinical cancer informatics · 2026Article
- Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma.Haematologica · 2025Article
- Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R/R LBCL.Blood advances · 2025Article
- Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma.HemaSphere · 2025Article
- Artificial intelligence and systems biology analysis in stem cell research and therapeutics development.Stem cells translational medicine · 2025Review
- Observational
- Noncanonical and mortality-defining toxicities of CAR T cell therapy.Nature medicine · 2025Review
- Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.Haematologica · 2025Review
- Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL.Blood advances · 2025Article
- Development and validation of predictive models of early immune effector cell-associated hematotoxicity.Blood advances · 2025Article
- Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes.Blood advances · 2025Article
- Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma.HemaSphere · 2025Article
- Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill.Current issues in molecular biology · 2024Review
- Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb.Pharmaceuticals (Basel, Switzerland) · 2024Review
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
Hematologic toxicity frequently complicates chimeric antigen receptor (CAR) T-cell therapy, resulting in significant morbidity and mortality. In an effort to standardize reporting, the European Hematology Association (EHA) and European Society of Blood and Marrow Transplantation (EBMT) devised the immune effector cell-associated hematotoxicity (ICAHT) grading system, distinguishing between early (day 0-30) and late (after day +30) events based on neutropenia depth and duration. However, manual implementation of ICAHT grading criteria is time-consuming and susceptible to subjectivity and error. To address these challenges, we introduce a novel computational approach, utilizing the R programming language, to automate early and late ICAHT grading. Given the complexities of early ICAHT grading, we benchmarked our approach both manually and computationally in two independent cohorts totaling 1251 patients. Our computational approach offers significant implications by streamlining grading processes, reducing manual time and effort, and promoting standardization across varied clinical settings. We provide this tool to the scientific community alongside a comprehensive implementation guide, fostering its widespread adoption and enhancing reporting consistency for ICAHT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.